About two-thirds of NSCLC patients carry EGFR mutations, which can benefit significantly from tyrosinase inhibitor TKI [22] because targeted drugs directly bind to the intracellular domain of EGFR to inhibit downstream signaling pathways. The gene discussed is TYR; the disease is non-small cell lung carcinoma.